N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine,High Purity

N-(5-AMINO-2-METHYLPHENYL)-4-(3-PYRIDYL)-2-PYRIMIDINEAMINE

Product information

English Name：N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine

English Alias：4-Methyl-N'-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine；

N-(5-amino-2-methylphenyl)-4-(3-pyrdyl)-2-pydimidineamine；

N-(5-amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine；

N-(5-amino-2-methylphenl)-4-(3-pyridyl)-2-pyrimidine-amine

Chinese Name：伊马胺

Chinese Alias：N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-氨基嘧啶；

 N-(5-氨基-2-甲基苯基l)-4-(3-吡啶)-2-嘧啶胺；

伊马替尼胺；伊玛胺；伊马替尼中间体(胺)

CAS号：152460-10-1

Forla：C16H15N5

Molecular weight：277.32

Appearance：White to light yellow power

Purity：98.0%

Use&Pharmacology

Imatinib intermediate.

Imatinib is the first-generation tyrosine kinase inhibitor and a milestone drug in the history of the treatment of chronic myeloid leukemia (CML). It was launched by Novartis in 2001 and is a successful model of targeted therapy. It only kills BCR-ABL contained in myeloid cells, prevents cell proliferation and tumor formation, but has no effect on normal cells. It can also inhibit PDGF-mediated tumors, including glioma and prostate cancer.

In the 1980s, scientific research showed that the granulocytes of most patients with chronic myelogenous leukemia had two chromosomes transposed, resulting in the fusion kinase BCR-ABL, which led to the continuous activation of the kinase activity, resulting in uncontrolled cell proliferation -Blood cancer. On this basis, Dr. Druker, a biologist at Oregon University of Health Sciences in the United States, proposed the hypothesis of using BCR-ABL as a drug target, and proposed the development of kinase inhibitors of this target to treat chronic myeloid leukemia. The second is the screening and optimization of the lead: Then, Druker and Novartis chemist Nick Lydon cooperated to select small molecule inhibitors that inhibit BCR-ABL kinase from the compound library and develop imatinib after optimization. Third, the results of preclinical research and clinical trials have shown that imatinib is safe and effective. The vast majority of chronic myelogen patients get complete hematological relief, and the side effects are much less than that of cytotoxic anti-tumor drugs.

Package&Storage

Package：1kg/bag, 10kg/drum, 25kg/drum (on request)

Storage&Validity：Cool, shading, dry and sealed/2years